The Spatial-Genomic Oncology Continuum

1. Cylindrical Bessel K₀ Transport

Governed by the steady-state Helmholtz equation ∇²C − λ⁻²C = 0. For outward divergent perivascular cords, the physical solution is C(r) = C₀ · K₀(r/λ) / K₀(r₀/λ). With λ ≈ 627.6 μm, small-molecule osimertinib falls below cellular IC₅₀ = 10 nM at r_crit = 165.9 μm, leaving a 34.1 μm vital shell (31.3% cord volume) with sub-therapeutic drug penetrance.

2. Invariant Lead-Time Kinetic Identity

The 5.4-month clinical window between ctDNA molecular detection (10⁷ cells) and radiographic CT relapse (10⁹ cells) is an invariant mathematical identity of exponential volume doubling:

for doubling time T_s = 24.6 days, exactly resolving the post-cessation ADAURA recurrence surge without de novo mutations.

3. The Composite Resistance Index (CRI)

Weights histological architecture (S), multi-gene co-mutation tier (G, Offin et al. JTO 2019), and stromal desmoplasia (M, Mori et al. 2015) to prospectively allocate patients into the Phase III SG-ADAURA clinical trial.

Subcellular spatial transcriptomics validation (N = 3,858 sequenced spots at 2 µm resolution captured across intact human EGFR-mutated lung adenocarcinoma). Demonstrating that physical microvascular rarefaction leaves >92% of the viable tumor mass beyond the critical osimertinib penetration radius (r_crit ≈ 165.9 µm), creating a persistent in-situ pharmacological sanctuary that fuels post-cessation recurrence.

GSE301973 Patient Spatial Profiling & Bedside CRI Stratification

Full 2D biophysical cross-section simulation running at 60 FPS. Simulating perivascular osimertinib diffusion (D_eff = 85 µm²/s), interstitial fluid pressure (IFP = 18 mmHg), subclonal competition, Month 36 drug cessation, and post-cessation recurrence dynamics across ADAURA vs. SG-ADAURA protocols.

🧠 Plain-Language Digest: The Spatial-Genomic Oncology Continuum

Sintesi divulgativa e clinica a cura del Dr. Luc Hendriks, PhD (Doctor in Sciences: Chemistry, Vrije Universiteit Brussel). Spiega la genesi del Paradosso ADAURA (la ripresa di malattia dopo la sospensione dell'Osimertinib a 36 mesi), il modello di diffusione biofisica di Bessel K₀ e la stratificazione del rischio terapeutico in un linguaggio rigoroso ma comprensibile a tutta la comunità multidisciplinare.